Neeraj Gupta

Neeraj Gupta

Takeda Pharmaceutical Company Limited - Osaka / Japan
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4406349
武田薬品工業株式会社
person_outline Neeraj Gupta's MOST POPULAR ARTICLES
1-) Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung CancerDR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ...New England Journal of Medicine 379 (21), 2027-2039, 20186572018
2-) Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trialDR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ...Journal of Clinical Oncology 38 (31), 3592-3603, 20203352020
3-) Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an …SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ...The Lancet Oncology 15 (13), 1503-1512, 20143342014
4-) Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ...The Lancet 393 (10168), 253-264, 20192682019
5-) Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaSK Kumar, WI Bensinger, TM Zimmerman, CB Reeder, JR Berenson, ...Blood, The Journal of the American Society of Hematology 124 (7), 1047-1055, 20142422014